CU20210092A7 - Péptidos bnip3 para el tratamiento de la lesión por reperfusión - Google Patents

Péptidos bnip3 para el tratamiento de la lesión por reperfusión

Info

Publication number
CU20210092A7
CU20210092A7 CU2021000092A CU20210092A CU20210092A7 CU 20210092 A7 CU20210092 A7 CU 20210092A7 CU 2021000092 A CU2021000092 A CU 2021000092A CU 20210092 A CU20210092 A CU 20210092A CU 20210092 A7 CU20210092 A7 CU 20210092A7
Authority
CU
Cuba
Prior art keywords
peptides
bnip3
treatment
reperfusion injury
bax
Prior art date
Application number
CU2021000092A
Other languages
English (en)
Inventor
Ulrike Hendgen-Cotta
Tienush Rassaf
Original Assignee
Bimyo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bimyo GmbH filed Critical Bimyo GmbH
Publication of CU20210092A7 publication Critical patent/CU20210092A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7019—Ischaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7038—Hypoxia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La invención proporciona péptidos capaces de inhibir la actividad individual y la comunicación entre rutas de BNIP3, BAX y mitocondria. Los péptidos se pueden utilizar en métodos para tratar una enfermedad o condición en un sujeto en el que es deseable prevenir el daño celular y la muerte celular.</p>
CU2021000092A 2019-05-10 2020-05-08 Péptidos bnip3 para el tratamiento de la lesión por reperfusión CU20210092A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19173715 2019-05-10
PCT/EP2020/062926 WO2020229362A1 (en) 2019-05-10 2020-05-08 Bnip3 peptides for treatment of reperfusion injury

Publications (1)

Publication Number Publication Date
CU20210092A7 true CU20210092A7 (es) 2022-06-06

Family

ID=66483874

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2021000092A CU20210092A7 (es) 2019-05-10 2020-05-08 Péptidos bnip3 para el tratamiento de la lesión por reperfusión

Country Status (15)

Country Link
US (1) US20220220174A1 (es)
EP (1) EP3966230A1 (es)
JP (1) JP2022532092A (es)
KR (1) KR20220007084A (es)
CN (1) CN114026114A (es)
AU (1) AU2020275076A1 (es)
BR (1) BR112021022156A2 (es)
CA (1) CA3138825A1 (es)
CO (1) CO2021015130A2 (es)
CU (1) CU20210092A7 (es)
EA (1) EA202192970A1 (es)
IL (1) IL287946A (es)
MX (1) MX2021013510A (es)
SG (1) SG11202112252UA (es)
WO (1) WO2020229362A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112608972B (zh) * 2020-12-21 2021-09-10 广东源心再生医学有限公司 Myog基因作为靶点在制备治疗心肌细胞凋亡相关的心血管疾病的药物中的应用
EP4333830A1 (en) * 2021-05-04 2024-03-13 Corvitus GmbH Method for inhibiting reperfusion injury
WO2023079141A2 (en) 2021-11-05 2023-05-11 Tienush Rassaf Amelioration and treatment of infarction damage

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2838444B1 (fr) * 2002-04-10 2016-01-01 Neovacs Nouveaux peptides et leur application en therapeutique
AU2003256636A1 (en) * 2002-07-22 2004-02-09 University Of Miami Preventing ischemia-induced cell damage
EP2072527A1 (en) * 2007-12-21 2009-06-24 Altonabiotec AG Fusion polypeptides comprising a SHBG dimerization component and uses thereof
US20130196922A1 (en) * 2010-07-21 2013-08-01 University Of Manitoba Bnip3 isoforms and methods of use

Also Published As

Publication number Publication date
AU2020275076A1 (en) 2021-11-25
MX2021013510A (es) 2022-02-11
US20220220174A1 (en) 2022-07-14
JP2022532092A (ja) 2022-07-13
CA3138825A1 (en) 2020-11-19
EA202192970A1 (ru) 2022-03-03
SG11202112252UA (en) 2021-12-30
CN114026114A (zh) 2022-02-08
EP3966230A1 (en) 2022-03-16
CO2021015130A2 (es) 2021-11-30
KR20220007084A (ko) 2022-01-18
WO2020229362A1 (en) 2020-11-19
BR112021022156A2 (pt) 2021-12-21
IL287946A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
CO2021015130A2 (es) Péptidos bnip3 para el tratamiento de la lesión por reperfusión
CO2021009078A2 (es) Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1)
CL2019002895A1 (es) Inhibidores de pd-1/pd-l1.
CL2020000215A1 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp.
CL2019001079A1 (es) Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina.
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
CO2020009861A2 (es) Inhibidores pd-1/pd-l1
ECSP18094983A (es) Derivados de pirazol como inhibidores de la calicreína plasmática
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
ECSP20077518A (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
CL2017000998A1 (es) Composición que comprende un agente de control biológico de la especie bacillus subtilis y un fungicida del grupo de inhibidores de la mitosis y la división celular, tal como fenamidona. (divisional solicitud 3272-2014)
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
UY38263A (es) Compuestos de purinona y su uso en el tratamiento del cáncer
PE20170140A1 (es) Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
DOP2014000104A (es) Compuesto heterocíclico dihidroxi aromático
ECSP21038390A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr
CL2022002808A1 (es) Inhibidores de kif18a para el tratamiento de enfermedades neoplásicas
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
BR112018000254A2 (pt) inibidores de pde9 com cadeia principal de imidazotriazinona e cadeia principal de imidazopirazinona para o tratamento de doenças periféricas
CL2017003133A1 (es) Uso de derivados de bencimidazol para escape ácido nocturno
ECSP23076906A (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
CO2017010151A2 (es) Material de implante compuesto
AR118585A1 (es) Métodos para tratar la hipertensión portopulmonar
CU20210008A7 (es) Aspirasas solubilizadas
ES2514140B1 (es) Uso del inhibidor de sulfatasas esteroideas STX64 para el tratamiento del envejecimiento